Peter J West1,2,3, Gerald W Saunders2, Peggy Billingsley2, Misty D Smith1,2,4, H Steve White5, Cameron S Metcalf1,2, Karen S Wilcox1,2,3. 1. Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah. 2. Epilepsy Therapy Screening Program (ETSP) Contract Site, University of Utah, Salt Lake City, Utah. 3. Interdepartmental Neuroscience Program, University of Utah, Salt Lake City, Utah. 4. School of Dentistry, University of Utah, Salt Lake City, Utah. 5. Department of Pharmacy, University of Washington, Seattle, Washington.
Abstract
OBJECTIVE: Approximately 30% of patients with epilepsy are refractory to existing antiseizure drugs (ASDs). Given that the properties of the central nervous systems of these patients are likely to be altered due to their epilepsy, tissues from rodents that have undergone epileptogenesis might provide a therapeutically relevant disease substrate for identifying compounds capable of attenuating pharmacoresistant seizures. To facilitate the development of such a model, this study describes the effects of classical glutamate receptor antagonists and 20 ASDs on recurrent epileptiform discharges (REDs) in brain slices derived from the kainate-induced status epilepticus model of temporal lobe epilepsy (KA-rats). METHODS: Horizontal brain slices containing the medial entorhinal cortex (mEC) were prepared from KA-rats, and REDs were recorded from the superficial layers. 6-cyano-7-nitroquinoxaline-2,3-dione, (2R)-amino-5-phosphonovaleric acid, tetrodotoxin, or ASDs were bath applied for 20 minutes. Concentration-dependent effects and half maximal effective concentration values were determined for RED duration, frequency, and amplitude. RESULTS: ASDs targeting sodium and potassium channels (carbamazepine, eslicarbazepine, ezogabine, lamotrigine, lacosamide, phenytoin, and rufinamide) attenuated REDs at concentrations near their average therapeutic plasma concentrations. γ-aminobutyric acid (GABA)ergic synaptic transmission-modulating ASDs (clobazam, midazolam, phenobarbital, stiripentol, tiagabine, and vigabatrin) attenuated REDs only at higher concentrations and, in some cases, prolonged RED durations. ASDs with other/mixed mechanisms of action (bumetanide, ethosuximide, felbamate, gabapentin, levetiracetam, topiramate, and valproate) and glutamate receptor antagonists weakly or incompletely inhibited RED frequency, increased RED duration, or had no significant effects. SIGNIFICANCE: Taken together, these data suggest that epileptiform activity recorded from the superficial layers of the mEC in slices obtained from KA-rats is differentially sensitive to existing ASDs. The different sensitivities of REDs to these ASDs may reflect persistent molecular, cellular, and/or network-level changes resulting from disease. These data are expected to serve as a foundation upon which future therapeutics may be differentiated and assessed for potentially translatable efficacy in patients with refractory epilepsy. Wiley Periodicals, Inc.
OBJECTIVE: Approximately 30% of patients with epilepsy are refractory to existing antiseizure drugs (ASDs). Given that the properties of the central nervous systems of these patients are likely to be altered due to their epilepsy, tissues from rodents that have undergone epileptogenesis might provide a therapeutically relevant disease substrate for identifying compounds capable of attenuating pharmacoresistant seizures. To facilitate the development of such a model, this study describes the effects of classical glutamate receptor antagonists and 20 ASDs on recurrent epileptiform discharges (REDs) in brain slices derived from the kainate-induced status epilepticus model of temporal lobe epilepsy (KA-rats). METHODS: Horizontal brain slices containing the medial entorhinal cortex (mEC) were prepared from KA-rats, and REDs were recorded from the superficial layers. 6-cyano-7-nitroquinoxaline-2,3-dione, (2R)-amino-5-phosphonovaleric acid, tetrodotoxin, or ASDs were bath applied for 20 minutes. Concentration-dependent effects and half maximal effective concentration values were determined for RED duration, frequency, and amplitude. RESULTS:ASDs targeting sodium and potassium channels (carbamazepine, eslicarbazepine, ezogabine, lamotrigine, lacosamide, phenytoin, and rufinamide) attenuated REDs at concentrations near their average therapeutic plasma concentrations. γ-aminobutyric acid (GABA)ergic synaptic transmission-modulating ASDs (clobazam, midazolam, phenobarbital, stiripentol, tiagabine, and vigabatrin) attenuated REDs only at higher concentrations and, in some cases, prolonged RED durations. ASDs with other/mixed mechanisms of action (bumetanide, ethosuximide, felbamate, gabapentin, levetiracetam, topiramate, and valproate) and glutamate receptor antagonists weakly or incompletely inhibited RED frequency, increased RED duration, or had no significant effects. SIGNIFICANCE: Taken together, these data suggest that epileptiform activity recorded from the superficial layers of the mEC in slices obtained from KA-rats is differentially sensitive to existing ASDs. The different sensitivities of REDs to these ASDs may reflect persistent molecular, cellular, and/or network-level changes resulting from disease. These data are expected to serve as a foundation upon which future therapeutics may be differentiated and assessed for potentially translatable efficacy in patients with refractory epilepsy. Wiley Periodicals, Inc.
Authors: Robert K Zahn; Else A Tolner; Christian Derst; Clemens Gruber; Rüdiger W Veh; Uwe Heinemann Journal: Neurobiol Dis Date: 2007-09-04 Impact factor: 5.996
Authors: Joseph V Raimondo; Uwe Heinemann; Marco de Curtis; Howard P Goodkin; Chris G Dulla; Damir Janigro; Akio Ikeda; Chou-Ching K Lin; Premysl Jiruska; Aristea S Galanopoulou; Christophe Bernard Journal: Epilepsia Date: 2017-11 Impact factor: 5.864
Authors: Misty D Smith; Gerald W Saunders; Rasmus P Clausen; Bente Frølund; Povl Krogsgaard-Larsen; Orla M Larsson; Arne Schousboe; Karen S Wilcox; H Steve White Journal: Epilepsy Res Date: 2008-02-08 Impact factor: 3.045
Authors: Xiaoyang Li; Richard A Himes; Lyndsey C Prosser; Charleston F Christie; Emma Watt; Sharon F Edwards; Cameron S Metcalf; Peter J West; Karen S Wilcox; Sherine S L Chan; C James Chou Journal: J Med Chem Date: 2020-05-22 Impact factor: 7.446
Authors: Oscar Alcoreza; Bhanu P Tewari; Allison Bouslog; Andrew Savoia; Harald Sontheimer; Susan L Campbell Journal: Epilepsia Date: 2019-06-18 Impact factor: 5.864